OnKure Therapeutics Secures $7 Million Series A Funding Led by Delian Capital to Advance Epigenetic Drug Pipeline

Image from the OnKure Therapeutics official website

On May 2, OnKure Therapeutics, a company focused on the research and development of epigenetic drugs, announced the completion of a $7 million Series A financing round. The round was led by Delian Capital, with participation from Longpan Capital, existing investors, and the company’s management team. The funds raised will be used to advance Phase I clinical trials of the company’s existing product candidates and to support the development of new products.

Headquartered in Colorado, USA, OnKure is a biopharmaceutical company dedicated to the research and development of targeted small-molecule drugs. Leveraging its epigenetics translation platform, the company is developing natural products with potential bioactivity for the treatment of cancer and other diseases.

OnKure’s core product is an orally bioavailable, selective Class I histone deacetylase (HDAC) inhibitor. Preclinical data to date have demonstrated a favorable safety profile for this agent. As epigenetic research advances, this oral, selective HDAC inhibitor holds promise for broader therapeutic applications in the future.

Meanwhile, the company is also advancing a series of new products, including selective HDAC6 inhibitors.

OnKure boasts an experienced management team. Dr. Tony Piscopio, the CEO, previously worked for many years at Amgen and Pfizer, and was also one of the founders of Array (ARRY), a NASDAQ-listed company. Professor Xuedong Liu, the Chief Scientific Officer (CSO), has focused his research on cell signaling and has made numerous outstanding contributions. Professor Gail Eckhardt, the Chief Medical Officer (CMO), serves as the Director of the LIVESTRONG Cancer Institutes at the University of Texas and has led multiple pioneering early-stage clinical trials.

Dr. Tony Piscopio, Co-founder and CEO of OnKure, stated, “We are honored to receive recognition from professional institutions such as Delian Capital. The proceeds from this financing round will be used to accelerate the clinical development of our core products and to introduce innovative products that have synergies with our R&D platform, thereby expanding our product portfolio.”

Zhao Guobao, Vice President of Delian Capital, stated, “Drug development grounded in deep biological research has always been the novel drug R&D strategy championed by Delian Capital. The OnKure management team boasts a successful track record in pharmaceutical entrepreneurship and extensive experience in drug research and development. Recent biological studies have revealed new application potential for HDAC inhibitors, and we are optimistic that OnKure will create greater value in the future through its development of epigenetic therapies.”